AFANDI

Afandi is a biotechnology company headquartered in Shanghai, China, that specializes in the development of Proteolysis Targeting Chimera (PROTAC) technology. The company has established a robust platform for protein degradation, focusing on the design and synthesis of novel E3 ligase ligands, linkers, and PROTAC molecules. Afandi offers a vast library of PROTAC building blocks and provides specialized CRO services to global pharmaceutical and biotech partners to accelerate the discovery of degraders for undruggable targets. Their internal research efforts are primarily directed toward oncology and immunology, targeting well-validated proteins such as the androgen receptor and BTK. By leveraging their expertise in medicinal chemistry and protein degradation, Afandi aims to develop next-generation therapeutics for complex diseases.